Correction to: npj Breast Cancer (2022) 8:98; https://doi.org/10.1038/s41523-022-00467-1, published online 29 August 2022
The article includes two typographical errors, on pages 5 and 6. On page 5, in the sentence beginning with “Dose interruptions…”, and on page 6, in the sentence beginning with “A higher frequency…”, the order of the percentage of patients in the SG and TPC arms who discontinued treatment due to adverse events in the ASCENT trial has been written backwards. Therefore, on page 5, values “26% and 22%, respectively” have been corrected to “22% and 26%, respectively”. Similarly, on page 6, values “(26% vs. 22%, respectively)” have been corrected to “(22% vs. 26%, respectively)”.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Rugo, H.S., Tolaney, S.M., Loirat, D. et al. Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. npj Breast Cancer 10, 41 (2024). https://doi.org/10.1038/s41523-024-00650-6
Published:
DOI: https://doi.org/10.1038/s41523-024-00650-6
- Springer Nature Limited